On the one hand, the role of KRAS mutations in the occurrence and development of PDAC has been basically clear, while on the other, the medicinal properties of KRAS gene have achieved a breakthrough in solid tumors such as lung cancer and colorectal cancer. This evidence concerns the gene KRAS and colorectal cancer.